Mehrzad Mirzania M.D. - Department of Hematology and Medical Oncology, Cancer Research Center, Cancer Institute of Iran, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran

The immune system plays main role in surveillance or eradication of some malignancy.mCRC is non-immunogenic in most cases (80 to 85%). combining tumor and immune factors todevelop and validate an immunoscore Is being created. This treatment is currently used fordMMR and MSI-H. In these patients T- lymphocyte infiltration has increased, which indicatestumor immunogens. There are three main articles in this area that indicate that immune therapy canbe effective. If one of the drugs in this category is not effective, it is still not advisable to useanother drug of the same category. In this session, we will explain the three new articles andrecommendations for immunotherapy in colon and rectal cancers.